Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Section METHODS: anti-CUGBP1 mice polyclonal antibody： page 7, line 11-12; anti-GAPDH: page 7, line 18; ERBB pathway-related antibody: page 7, line 19-21.	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	Section METHODS: Page 5, line 7-11.	
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		n/a: our research does not relate to the primary cultures.

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		n/a: our research does not relate to the in vivo experiment.
Animal observed in or captured from the field: Provide species, sex and age where possible		n/a: our research does not relate to the in vivo experiment.
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		n/a: our research does not relate to the in vivo experiment.

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		n/a: our research does not relate to Plants.
Microbes: provide species and strain, unique accession number if available, and source		n/a: our research does not relate to Microbes.

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Section METHODS: Page 5, line 17-19.	
Provide statement confirming informed consent obtained from study participants.	Section METHODS: Page 5, line 17-19.	
Report on age and sex for all study participants.	Section METHODS table 1: Age and sex information was provided in table 1(page 5 line 24).	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.		n/a: not a clinical trial

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	Section METHODS: From page 5, line 6 to page 9, line 22	

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination		n/a: not a clinical trial
Randomisation		n/a: not a clinical trial
Blinding		n/a: not a clinical trial
Inclusion/exclusion criteria		n/a: not a clinical trial

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Section METHODS: Page 9 line 21-22.	
Define whether data describe technical or biological replicates	Section METHODS: Page 9 line 21-22.	

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a: not a clinical trial
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a: our research does not relate to the in vivo experiment.
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Section METHODS: Page 5 line 17-19.	

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		n/a: the study was not subjected to DURC.

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		n/a: not a clinical trial

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Section METHODS: Page 9 line 17-22.	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	Section Data Sharing Statement: Page 15 line 16-17.	
If data are publicly available, provide accession number in repository or DOI or URL.	Section METHODS: Page 6 line 18-23.	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		n/a: publicly available data was not reused.

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		n/a: have no newly generated code and software.
If code is publicly available, provide accession number in repository, or DOI or URL.		n/a: have no newly generated code and software.

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/tcr-21-311